Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Peripheral Neuropathic PainNociceptive Pain

Interventions

DRUG

AZD3161

Single dose, intradermal injection

DRUG

Lidocaine

Single dose, intradermal injection

DRUG

AZD3161 Placebo

Trial Locations (1)

Research Site, London